FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282938966> ?p ?o ?g. }

• W4282938966 endingPage "3213" @default.
• W4282938966 startingPage "3207" @default.
• W4282938966 abstract "Abstract Purpose: To explore the efficacy of retreatment with immune checkpoint inhibitors (ICI) in patients with advanced non–small cell lung cancer (NSCLC) who responded to prior ICI and had adequate ICI-free interval. Patients and Methods: Patients with advanced NSCLC who had achieved complete response (CR), partial response (PR), or stable disease for ≥6 months with prior ICI therapy preceding progression were prospectively enrolled. All patients should have had ICI-free interval ≥60 days before registration. Patients were treated with nivolumab (240 mg) every 2 weeks until progression. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival, and safety (Trial Identifier, UMIN000028561). Results: Sixty-one patients were enrolled during October 2017 to February 2020, with 59 analyzed for efficacy. Regarding prior ICI, 41 patients had CR or PR. Median treatment on ICI and median ICI-free intervals were 8.1 months and 9.2 months, respectively. Twenty patients experienced immune-related adverse events (irAE) that required discontinuation of prior ICI. Nivolumab retreatment demonstrated ORR of 8.5% [95% confidence interval (CI), 2.8–18.7%] and median PFS of 2.6 months (95% CI, 1.6–2.8 months) while 5 responders had 11.1 months of median PFS. In the multivariate analysis, ICI-free interval was the only predictive factor of PFS (HR, 2.02; P = 0.02), while prior efficacy or history of irAE was not. Common adverse events were skin disorders (23%), malaise (20%), and hypoalbuminemia (15%). Conclusions: Even in patients who initially responded to prior ICI and had ICI-free interval, once resistance occurred, retreatment with nivolumab had limited efficacy." @default.
• W4282938966 created "2022-06-16" @default.
• W4282938966 creator A5002745221 @default.
• W4282938966 creator A5024261346 @default.
• W4282938966 creator A5028078831 @default.
• W4282938966 creator A5028506413 @default.
• W4282938966 creator A5032337115 @default.
• W4282938966 creator A5035314420 @default.
• W4282938966 creator A5038101792 @default.
• W4282938966 creator A5054386489 @default.
• W4282938966 creator A5062708568 @default.
• W4282938966 creator A5064708494 @default.
• W4282938966 creator A5069784331 @default.
• W4282938966 creator A5073895575 @default.
• W4282938966 creator A5078647935 @default.
• W4282938966 creator A5080938148 @default.
• W4282938966 creator A5084260472 @default.
• W4282938966 creator A5091306013 @default.
• W4282938966 date "2022-05-26" @default.
• W4282938966 modified "2023-10-04" @default.
• W4282938966 title "Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)" @default.
• W4282938966 cites W1498931318 @default.
• W4282938966 cites W1982488143 @default.
• W4282938966 cites W2074999094 @default.
• W4282938966 cites W2560367415 @default.
• W4282938966 cites W2562305489 @default.
• W4282938966 cites W2572174216 @default.
• W4282938966 cites W2591493010 @default.
• W4282938966 cites W2924703624 @default.
• W4282938966 cites W2925781938 @default.
• W4282938966 cites W2948397884 @default.
• W4282938966 cites W2955392295 @default.
• W4282938966 cites W2978412906 @default.
• W4282938966 cites W3008374819 @default.
• W4282938966 cites W3016806376 @default.
• W4282938966 cites W3082365058 @default.
• W4282938966 cites W3139265240 @default.
• W4282938966 cites W3152878368 @default.
• W4282938966 cites W3153820261 @default.
• W4282938966 cites W3154805493 @default.
• W4282938966 cites W3159504492 @default.
• W4282938966 cites W3196898938 @default.
• W4282938966 cites W4206362366 @default.
• W4282938966 doi "https://doi.org/10.1158/1078-0432.ccr-22-0602" @default.
• W4282938966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35617519" @default.
• W4282938966 hasPublicationYear "2022" @default.
• W4282938966 type Work @default.
• W4282938966 citedByCount "5" @default.
• W4282938966 countsByYear W42829389662022 @default.
• W4282938966 countsByYear W42829389662023 @default.
• W4282938966 crossrefType "journal-article" @default.
• W4282938966 hasAuthorship W4282938966A5002745221 @default.
• W4282938966 hasAuthorship W4282938966A5024261346 @default.
• W4282938966 hasAuthorship W4282938966A5028078831 @default.
• W4282938966 hasAuthorship W4282938966A5028506413 @default.
• W4282938966 hasAuthorship W4282938966A5032337115 @default.
• W4282938966 hasAuthorship W4282938966A5035314420 @default.
• W4282938966 hasAuthorship W4282938966A5038101792 @default.
• W4282938966 hasAuthorship W4282938966A5054386489 @default.
• W4282938966 hasAuthorship W4282938966A5062708568 @default.
• W4282938966 hasAuthorship W4282938966A5064708494 @default.
• W4282938966 hasAuthorship W4282938966A5069784331 @default.
• W4282938966 hasAuthorship W4282938966A5073895575 @default.
• W4282938966 hasAuthorship W4282938966A5078647935 @default.
• W4282938966 hasAuthorship W4282938966A5080938148 @default.
• W4282938966 hasAuthorship W4282938966A5084260472 @default.
• W4282938966 hasAuthorship W4282938966A5091306013 @default.
• W4282938966 hasBestOaLocation W42829389661 @default.
• W4282938966 hasConcept C121608353 @default.
• W4282938966 hasConcept C126322002 @default.
• W4282938966 hasConcept C141071460 @default.
• W4282938966 hasConcept C197934379 @default.
• W4282938966 hasConcept C203092338 @default.
• W4282938966 hasConcept C207103383 @default.
• W4282938966 hasConcept C2776256026 @default.
• W4282938966 hasConcept C2776694085 @default.
• W4282938966 hasConcept C2777701055 @default.
• W4282938966 hasConcept C2778715236 @default.
• W4282938966 hasConcept C2778822529 @default.
• W4282938966 hasConcept C2779984678 @default.
• W4282938966 hasConcept C2780030458 @default.
• W4282938966 hasConcept C2780739268 @default.
• W4282938966 hasConcept C44249647 @default.
• W4282938966 hasConcept C535046627 @default.
• W4282938966 hasConcept C71924100 @default.
• W4282938966 hasConcept C90924648 @default.
• W4282938966 hasConceptScore W4282938966C121608353 @default.
• W4282938966 hasConceptScore W4282938966C126322002 @default.
• W4282938966 hasConceptScore W4282938966C141071460 @default.
• W4282938966 hasConceptScore W4282938966C197934379 @default.
• W4282938966 hasConceptScore W4282938966C203092338 @default.
• W4282938966 hasConceptScore W4282938966C207103383 @default.
• W4282938966 hasConceptScore W4282938966C2776256026 @default.
• W4282938966 hasConceptScore W4282938966C2776694085 @default.
• W4282938966 hasConceptScore W4282938966C2777701055 @default.
• W4282938966 hasConceptScore W4282938966C2778715236 @default.
• W4282938966 hasConceptScore W4282938966C2778822529 @default.
• W4282938966 hasConceptScore W4282938966C2779984678 @default.

• next